Ursula A. Matulonis, MD, is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She is Co-Leader of the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the National Cancer Institute. She also is the co-PI of a P01 Program Project Grant entitled: Targeting Replication Stress and DNA Damage Response in Uterine Cancer at Dana-Farber.
Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, antibody drug conjugate, and combination targeted therapy trials for ovarian cancer in the United States and internationally. She is the chair of the Gynecologic Cancer subcommittee of the National Cancer Institute (NCI) cooperative group, Alliance, and is a member of the NCI Gynecologic Cancer Steering committee. She is an Associate Editor of Gynecologic Oncology. She has received the Dana-Farber Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, the Clearity Foundation award, the Zakim Award at Dana-Farber for patient advocacy, the Albany Medical College Alumni Association Distinguished Alumna Award and, in 2022, the Rosalind Franklin Prize for Excellence in Ovarian Cancer Research from the Ovarian Cancer Research Alliance in 2022.
After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA.